Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Non Operating Income: 2010-2025

Historic Non Operating Income for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to $1.8 million.

  • Altimmune's Non Operating Income fell 4.01% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 30.24%. This contributed to the annual value of $8.1 million for FY2024, which is 8.43% up from last year.
  • Latest data reveals that Altimmune reported Non Operating Income of $1.8 million as of Q3 2025, which was up 137.76% from $776,000 recorded in Q2 2025.
  • Altimmune's Non Operating Income's 5-year high stood at $2.4 million during Q1 2024, with a 5-year trough of -$306,000 in Q3 2021.
  • In the last 3 years, Altimmune's Non Operating Income had a median value of $1.9 million in 2023 and averaged $1.8 million.
  • In the last 5 years, Altimmune's Non Operating Income slumped by 558.35% in 2021 and then surged by 1,870.37% in 2022.
  • Quarterly analysis of 5 years shows Altimmune's Non Operating Income stood at -$81,000 in 2021, then soared by 1,870.37% to $1.4 million in 2022, then soared by 38.21% to $2.0 million in 2023, then decreased by 14.93% to $1.7 million in 2024, then dropped by 4.01% to $1.8 million in 2025.
  • Its Non Operating Income stands at $1.8 million for Q3 2025, versus $776,000 for Q2 2025 and $1.6 million for Q1 2025.